-

Fresenius Kabi Introduces KabiCare Nutrition Resources for U.S. Parenteral Nutrition Products

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced KabiCare Nutrition Resources in the United States as part of its KabiCare patient support program. The KabiCare Nutrition Resources program provides support for insurance reimbursement questions including a helpline staffed by experts to provide billing and coding support, insurance support such as benefit investigation, prior authorization and claims appeals. More information about KabiCare Nutrition Resources can be found at kabicare.us.

“Navigating the complexity of health insurance to provide access to critical parenteral nutrition products continues to be a challenge for some patients,” said Tom Tsilipetros, senior director, Market Access, at Fresenius Kabi USA. ”As a leader in parenteral nutrition, Fresenius Kabi’s goal with the KabiCare Nutrition Resources program in the U.S. is to help assure patients receive their care and parenteral nutrition products in as timely a manner, and as seamlessly, as possible.”

About KabiCare, a Patient Support Program

Fresenius Kabi created KabiCare, a Patient Support Program, to support patient access to products across numerous therapeutic areas. KabiCare provides a patient-centric approach which includes support and resources for eligible patients, caregivers, and health care providers throughout the treatment journey. For eligible patients, support may include navigating complex insurance processes as well as financial assistance. For additional information, please call 1-833-KABICARE or visit kabicare.us.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi and Phlow Corp. Announce First-Ever, End-to-End, U.S. Manufacturing Collaboration for Epinephrine Injection, USP

LAKE ZURICH, Ill. & RICHMOND, Va.--(BUSINESS WIRE)--Fresenius Kabi and Phlow Corp. announced today a first-of-its-kind collaboration to onshore the manufacture of Epinephrine Injection, USP, an essential medicine long at risk of chronic shortage in the U.S. and widely used in hospitals nationwide. The arrangement, which includes the domestic manufacture of active pharmaceutical ingredients (APIs) and finished doses, is designed to be scalable to other essential medicines. Under the agreement, P...

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has been certified by the Top Employers Institute as a 2026 Top Employer in the United States and North America. This affirms the company’s ongoing commitment to creating a positive work environment. Globally, Fresenius Kabi was certified as a Top Employer for 2026 in 13 countries and two regions. Since 2023, Fre...

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing. Frese...
Back to Newsroom